Highest-materiality recent filing
MeiraGTx Q2 net income $160.7M; bota-vec acquired, $400M Oberland deal, BTD for AAV2-hAQP1
Q2 net income $160.7M ($1.76 basic EPS) vs net loss $38.8M in Q2 2025; revenue from services and licenses surged.
MeiraGTx secures up to $400M from Oberland Capital in royalty and equity deal
Initial $135M funded: $125M in exchange for low single-digit capped royalties on three products, plus $10M equity investment at $10.52/share.
MeiraGTx shareholders elect three Class II directors and ratify Ernst & Young as auditor
Annual meeting held June 11, 2026; 75,326,022 shares (81.4%) represented.
MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M
Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.
MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV
Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.
MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia
62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.
MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment
MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.
MeiraGTx prices $100M public offering of 11.1M shares at $9.00 each; net proceeds ~$93.3M
11,111,111 ordinary shares at $9.00/sh; net proceeds ~$93.3M after underwriting discounts and expenses.
MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.
MeiraGTx repurchases 2.3M shares from Perceptive Master Fund for $18.2M at $7.91 per share
Bought 2,300,000 ordinary shares from Perceptive Life Sciences Master Fund at VWAP of $7.91, aggregate $18.2M.
MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront
Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.
MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones
Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.
MeiraGTx Q2 net loss narrows to $38.8M; FDA alignment on RIX pivotal study, RMAT for Parkinson's
Net loss $38.8M ($0.48/sh) vs $48.6M ($0.76/sh) in Q2 2024; cash $32.2M at June 30, 2025.
MeiraGTx receives UK FDI clearances for Hologen deal; closing expected July 2025
UK foreign direct investment clearances obtained for proposed transactions with Hologen Limited.
MeiraGTx annual meeting elects director, ratifies auditor
Director Thomas E. Shenk elected with 40.3M votes for, 9.1M withheld, 9.9M broker non-votes.
MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD
Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.
FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease
RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).
MeiraGTx enters 7yr7mo lease for 14,235 sq ft NYC lab; terminates prior sublease
New lease with ARE-East River Science Park for lab/office space at $111/sq ft/yr, 3% annual escalations.
MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD
Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.
MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia
FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.
MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M
AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.
AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.
MeiraGTx closes public offering of 12.5M shares at $4.00, netting $48.3M
Public offering of 12,500,000 ordinary shares at $4.00/share completed August 13, 2024; net proceeds ~$48.3M.
MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi
Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.
MeiraGTx 2024 AGM results: directors elected, say-on-pay approved, auditor ratified
Three Class III directors elected: Forbes (99.8% cast, 49.6M for), Harris (99.5%), Mendoza (99.7%).
MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen
Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.
MeiraGTx amends prior 8-K to disclose Dr. Debra Yu's committee appointments
Debra Yu, M.D., joined the Board on April 25, 2022; this amendment adds committee assignments.
MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone
Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.
MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study
$50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).
MeiraGTx sells bota-vec rights to J&J's Janssen for up to $415M; $130M upfront/near-term
Upfront $65M at signing; additional $50M expected Q1 2024 and $15M later, totaling $130M near-term.
MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share
Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.
Sanofi subsidiary purchased 4M ordinary shares at $7.50 each for gross proceeds of $30M; shares subject to 18-month lock-up and standstill for 24 months.
MeiraGTx Q2 net loss $29.6M; Phase 3 XLRP trial enrollment surpassed; secures $25M note amendment
Q2 2023 net loss $29.6M ($0.53/share) vs $34.0M ($0.76) YoY; license revenue $3.5M (down from $10.8M).
MeiraGTx annual meeting results: all director nominees elected, auditor ratified
Turnout of 77.3% (37,669,017 shares) at annual meeting on June 8, 2023.
MeiraGTx Q1 net loss $30.4M; raises $60M PIPE; BLA on track for 2024
Net loss $30.4M ($0.62/share) vs $31.0M ($0.70) in Q1 2022; cash $68.8M at March 31, 2023.
MeiraGTx raises $62M in private placement at $5.75/share
Sold 10,773,913 ordinary shares at $5.75/share for gross proceeds of ~$62M; closed May 5, 2023.
Director Arnold J. Levine resigns from MeiraGTx board for health reasons
Arnold J. Levine, Ph.D. resigned from the Board effective April 21, 2023.
MeiraGTx reports 2022 net loss $129.6M; pipeline advances toward 2024 BLA
Net loss of $129.6M ($2.87/share) vs $79.6M in 2021; revenue $15.9M (down from $37.7M on lower milestone payments).
MeiraGTx discloses no exposure to Silicon Valley Bank
Company does not hold cash deposits or securities with Silicon Valley Bank.
MeiraGTx reports Q3 2022 net loss $37.3M; receives $25M investment from JJDC
Net loss of $37.3M ($0.83 per share) vs $25.9M ($0.59) in Q3 2021.
MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024
Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.
$75M initial term loan from Perceptive Advisors, with option for additional $25M; interest at 10% + SOFR, maturity Aug 2026.
Director Joel S. Marcus resigns from MeiraGTx board, effective immediately
Joel S. Marcus resigned from Board of Directors and all committees, effective June 27, 2022.
MeiraGTx shareholders elect three Class I directors, ratify EY as auditor
75.2% of outstanding ordinary shares were present or represented at June 7, 2022 AGM.
MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing
Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.
MeiraGTx appoints Debra Yu, MD to Board of Directors
Dr. Yu appointed effective April 25, 2022 as Class II director; term expires at 2023 annual meeting.
MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances
Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.
6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.
MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps
Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.
MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023
Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.
On April 21, 2023, Arnold J. Levine, Ph.D. tendered his resignation from the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”) and the committees of the Board on which he serves, in each case, effective immediately.
On June 27, 2022, Joel S. Marcus tendered his resignation from the Board of Directors (the “Board”) of MeiraGTx Holdings plc and the committees of the Board on which he serves, in each case, effective immediately.
On April 25, 2022, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Debra Yu, M.D. to the Board as a Class II director, effective immediately, with a term that expires at the Company’s 2023 annual meeting of shareholders and until her successor is duly elected and qualified.
Max materiality 0.90 · Median 0.70 · Most common event earnings